Tg Therapeutics (TGTX) Non-Current Debt (2010 - 2026)

Tg Therapeutics' Non-Current Debt history runs 15 years deep, the most recent figure standing at $745.1 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 204.47% year-over-year to $745.1 million in Q1 2026; TTM through Mar 2026 was $745.1 million, a 204.47% increase from a year earlier, with the FY2025 full-year figure at $245.6 million, changed 0.5% from the prior year.
• Non-Current Debt improved to $745.1 million in Q1 2026 per TGTX's latest filing, from $245.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $745.1 million in Q1 2026 and bottomed at $67.2 million in Q1 2022.
• The 5-year median for Non-Current Debt is $101.3 million (2024), against an average of $181.8 million.
• Across the five-year window, Non-Current Debt increased 0.48% in 2025 and soared 204.47% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $71.1 million in 2022, then jumped by 40.74% to $100.1 million in 2023, then jumped by 144.14% to $244.4 million in 2024, then rose by 0.5% to $245.6 million in 2025, then surged by 203.34% to $745.1 million in 2026.
• Per Business Quant, the three latest TGTX Non-Current Debt figures stand at $745.1 million (Q1 2026), $245.6 million (Q4 2025), and $245.3 million (Q3 2025).